Beth Sheedy

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Colin D. Weekes, Daniel D. Von Hoff, Alex A. Adjei et al. · Clinical Cancer Research · 2013 · 60 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naive Subjects

Graeme Moyle, Marta Boffito, Albrecht Stoehr et al. · Antimicrobial Agents and Chemotherapy · 2010 · 41 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

LP37 : A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases

Mitchell L. Shiffman, B. Freilich, Raj Vuppalanchi et al. · Journal of Hepatology · 2015 · 30 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034

D. Bissett, Howard L. McLeod, Beth Sheedy et al. · British Journal of Cancer · 2001 · 24 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

John D. Roberts, Stephen Shibata, Darcy Spicer et al. · Cancer Chemotherapy and Pharmacology · 2000 · 15 citations

Pharmacy, Pharmacology, Pharmacotherapy +4